Instructure Inc. (INST) Breaks into New 52-Week High on October 10 Session

Equities Staff  |

Shares of Instructure Inc. (INST) broke into a new 52-week high yesterday, hitting a peak of $35.60. Shares closed at $34.20 after opening at $34.80 for a move of -1.44%. The company now has a market cap of $1.01 billion.

Investors and traders can learn a lot about a stock’s momentum when it sets a new 52-week high. As an example, bullish investors view a company hitting its highest price in a year as a sign of momentum and may interpret it as a signal to buy. On the other hand, bearish investors could view a new 52-week high as a signal of the end of a strong run, with the stock possibly peaking out before an impending period of decline.

For Instructure Inc., the new 52-week high came on volume of 149,120. The stock has a float of 29.4 million shares and average daily volume of $306,419. It has a 50-day SMA of $31.61 and a 200-day SMA of $26.34.

For a complete fundamental analysis analysis of Instructure Inc., check out’s Stock Valuation Analysis report for INST.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit to learn more about Guild Investment’s Market Commentary and Adam Sarhan’s Find Leading Stocks today.

Instructure, Inc. provides cloud-based learning management platform for academic institutions and companies worldwide. The company offers its platform through a Software-as-a-Service business model.

Instructure Inc. is based out of Salt Lake City, UT and has some 1,099 employees. Its CEO is Joshua L. Coates.

Instructure Inc. is also a component of the Russell 2000 Index, which is an invaluable tool for any small-cap investor. Consisting of the smaller 2,000 publicly traded companies of the 3,000 largest companies in America by market cap (which combine to make the broader Russell 3000 index), the Russell 2000 gives the most comprehensive snapshot of the small-cap market of any index out there.

What's more, the Russell 2000 is maintained by Russell Investments, a company committed to using rules-based methodologies to construct unbiased indices that differ from the committee-selected Dow Jones Industrial Average or S&P 500.

To get more information on Instructure Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: INST’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.